VxP Pharma
VxP Pharma is a US-based CDMO in Indianapolis providing contract development, sterile injectable manufacturing, lyophilization, biologics, viral vector, and preclinical safety services to pharmaceutical and biotechnology companies.
- Company typePrivate
- Founded2010
- HeadquartersIndianapolis, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What VxP Pharma does
VxP Pharma is a US-based contract development and manufacturing organization (CDMO) headquartered at Purdue Research Park in Indianapolis, Indiana. Founded in 2010, the company provides pharmaceutical development and manufacturing services for the global pharmaceutical and biotech industry, spanning R&D scale work (including toxicology supplies) through clinical trial materials to niche commercial manufacturing. Its primary customers are pharmaceutical and biotechnology companies requiring specialized capabilities in sterile injectable manufacturing (vials and pre-filled syringes), lyophilization, biologics development (including live virus products), viral vector and viral vaccine services, and preclinical safety evaluation studies supporting IND and NDA regulatory submissions.
The company's core technical platform is built around US FDA-inspected facilities offering an integrated service portfolio under a single roof. Capabilities include preformulation and solid-state chemistry (polymorph screening, salt synthesis, cocrystal analysis, amorphous solid dispersions), biologics and live virus biomanufacturing, sterile dosage form manufacturing, lyophilization (freeze-drying), and in-vivo and in-vitro preclinical safety evaluation. The company works with both biologics (including live virus) and small molecule programs, addressing complex dosage form requirements that are difficult to source from generalist manufacturers.
VxP Pharma generates revenue through a professional services / contract manufacturing model, with pricing likely quote-based and tied to project scope, volume, and service requirements. The company employs an enterprise field sales motion, engaging clients through direct consultative technical engagement and a website-driven "Get Started" / "Contact" lead capture. The business is privately held and founder-led by Raymond E. Peck, operating through two wholly-owned subsidiaries: VxP Pharma Services (general pharmaceutical contract manufacturing) and VxP Biologics (biologics-focused). No institutional investment, public ownership, or revenue disclosures were found in available data.
VxP Pharma firmographics
Firmographics- Name
- VxP Pharma
- Legal name
- VxP Pharma, Inc.
- Website
- https://vxppharma.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- VxP Pharma is a US-based CDMO in Indianapolis providing contract development, sterile injectable manufacturing, lyophilization, biologics, viral vector, and preclinical safety services to pharmaceutical and biotechnology companies.
- Ownership category
- akta.pro rank
VxP Pharma industry classification
Industry- Product category
- Pharmaceutical Contract Development and Manufacturing (CDMO)
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
- akta.pro secondary industries
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Cell Therapy CDMO (HLAGABAD)
Keywords
Where VxP Pharma is headquartered
LocationHeadquarters
- HQ city
- Indianapolis
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
VxP Pharma business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- Contract Development and Manufacturing Services: VxP Pharma generates revenue through contract development and manufacturing services for pharmaceutical and biotech companies. Services span from R&D scale (including toxicology supplies) through clinical trial materials to niche commercial manufacturing. The company works with multiple dosage forms including sterile injectables and lyophilized products for biologics and small molecule programs.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
VxP Pharma product offering
Product offeringCore offering
VxP Pharma is a US-based Contract Development and Manufacturing Organization (CDMO) that provides pharmaceutical development and manufacturing services spanning R&D scale (including tox supplies), clinical trial materials, and niche commercial manufacturing. The company operates from US FDA-inspected facilities in Indianapolis, Indiana, and works with both biologics (including live virus products) and small molecule programs across dosage forms including sterile injectables (vials and pre-filled syringes) and lyophilized products. Its preclinical group also provides in-vivo and in-vitro safety evaluation studies supporting IND and NDA submissions.
Product overview
VxP Pharma is a US-based CDMO offering Contract Development and Manufacturing services for the global pharmaceutical and biotech industry. The company provides an integrated portfolio of services spanning from R&D scale (including tox supplies) through clinical trial materials to niche commercial manufacturing. Core offerings include Viral Vector and Viral Vaccines, Manufacturing of Sterile Dosage Forms (vials and pre-filled syringes), Biologic Development and Biomanufacturing, Lyophilization, Preclinical Safety Evaluation, and Preformulation and Solid-State Chemistry services. The company operates US-FDA inspected facilities and works with both biologics (including live virus) and small molecule programs across multiple dosage forms including sterile injectables and lyophilized products.
Differentiator
Problem solved
Functional benefit
Products and services
- Contract Development and Manufacturing (CDMO) Full-service CDMO providing pharmaceutical development and manufacturing services spanning R&D scale (including tox supplies), clinical trial materials, and niche commercial manufacturing for biologics (including live virus) and small molecule programs.
- Viral Vector and Viral Vaccines Services
- Manufacturing – Sterile Dosage Forms
- Biologic Development and Biomanufacturing Services
- Lyophilization
- Preclinical Services
- Preformulation and Solid-State Chemistry
Companies that use VxP Pharma
Customer profileSegments3 records
Ideal customer profiles2 records
VxP Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
VxP Pharma partnerships and signals
Strategic signalScale indicators1 record
Recent moves5 records
Expansion highlights3 records
VxP Pharma competitors and assessment
Company assessmentDirect peers
- Siegfried Holding: Swiss CDMO providing API and drug product manufacturing, including sterile fill-finish. Overlaps with VxP on small-molecule drug product and parenteral manufacturing.
- Recipharm: European-headquartered CDMO offering sterile injectables, lyophilization, and biologics services. Closely comparable to VxP across sterile and biologic drug product manufacturing.
- AGC Biologics: Mid-sized CDMO focused on biologics, cell and gene therapy, and viral vector manufacturing. Closely comparable to VxP in biologics and live virus services, though with a broader global footprint.
- Piramal Pharma Solutions: Contract development and manufacturing organization offering sterile injectables, biologics, and small-molecule services. Comparable to VxP in integrated service offering, but operates at a larger scale globally.
Broad incumbents
- Catalent: Global CDMO leader with extensive sterile injectable, biologics, and lyophilization capabilities. Directly comparable in service mix, but operates at vastly greater scale and a broader geographic footprint than VxP.
- Lonza Group: One of the largest global CDMOs with deep biologics, cell and gene therapy, and small-molecule capabilities. Overlaps with VxP on biologics manufacturing and viral vector services, but at a vastly larger scale.
- Thermo Fisher Scientific (Patheon): Operates a large pharma services business through Patheon covering drug substance, drug product, and clinical manufacturing. Direct overlap with VxP's CDMO service portfolio at significantly greater scale and global reach.
Emerging players
- Ardena: Smaller CDMO offering drug substance, drug product, and analytical services with a focus on smaller biotech clients. Similar in scale to VxP and overlapping on preformulation and small-molecule development.
- Center for Breakthrough Medicines: Specialty CDMO focused on cell and gene therapy manufacturing, including viral vectors. Comparable to VxP on viral vector services, though concentrated in the cell/gene therapy niche.
Others
- BioReliance (Merck KGaA): Merck KGaA's biopharmaceutical testing and manufacturing services business, providing biologics safety testing and viral clearance services. Comparable to VxP's preclinical safety evaluation offering.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
VxP Pharma social profiles
Digital presenceVxP Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
VxP Pharma leadership team
Management profileNumber of profiles
Profiles2 records
VxP Pharma subsidiaries and ownership
Company hierarchySubsidiaries2 records
VxP Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
VxP Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about VxP Pharma
What does VxP Pharma do?
VxP Pharma is a US-based Contract Development and Manufacturing Organization (CDMO) that provides pharmaceutical development and manufacturing services spanning R&D scale (including tox supplies), clinical trial materials, and niche commercial manufacturing. The company operates from US FDA-inspected facilities in Indianapolis, Indiana, and works with both biologics (including live virus products) and small molecule programs across dosage forms including sterile injectables (vials and pre-filled syringes) and lyophilized products. Its preclinical group also provides in-vivo and in-vitro safety evaluation studies supporting IND and NDA submissions.
Is VxP Pharma a public or private company?
VxP Pharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was VxP Pharma founded?
VxP Pharma was founded in 2010. It employs 11 to 50 people.
Where is VxP Pharma based?
VxP Pharma is headquartered in Indianapolis, United States, in the North America region.
How does VxP Pharma make money?
One revenue line is on record: contract Development and Manufacturing Services.
Who are VxP Pharma's main competitors?
Direct peers on record are Siegfried Holding, Recipharm, AGC Biologics and Piramal Pharma Solutions. Broad incumbents are Catalent, Lonza Group and Thermo Fisher Scientific (Patheon). Emerging players are Ardena and Center for Breakthrough Medicines. BioReliance (Merck KGaA) is listed as an others.
Does VxP Pharma have an API?
No public API is recorded for VxP Pharma.
What industry is VxP Pharma in?
VxP Pharma's product category is Pharmaceutical Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO. Its NAICS code is 325412 and its SIC code is 2834.